Novaliq GmbH   Report issue

For profit Phase 2 Phase 3
Founded: Heidelberg Germany (2007)

Organization Overview

First Clinical Trial
2014
NCT02113293
First Marketed Drug
2023
cyclosporine (sandimmune)
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Betaliq, Inc. | Novaliq GmbH | NOVALIQ GMBH